Innovative Protein Degraders for Targeted Cancer and Viral Therapy

ACS Medicinal Chemistry Letters, Journal Year: 2025, Volume and Issue: 16(2), P. 222 - 223

Published: Jan. 29, 2025

The development of targeted protein degraders offers novel strategies for treating cancer and chronic viral infections. This Patent Highlight integrates bifunctional degraders, leveraging autophagy via p62, substituted oxazolone compounds targeting IKZF1–4 transcription factors. These demonstrate exceptional efficacy in degrading pathogenic proteins, reprogramming immune responses, facilitating tumor immunity. dual approach underscores the potential cellular degradation systems precision medicine.

Language: Английский

Exploiting E3 Ligases for Lung Cancer Therapy: The Promise of DCAF-PROTACs

Pathology - Research and Practice, Journal Year: 2025, Volume and Issue: 270, P. 156001 - 156001

Published: May 10, 2025

Language: Английский

Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia

Investigational New Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: May 14, 2025

Language: Английский